This application is for a Mentored Clinical Scientist Development Award (MCSDA). Previously, in the laboratory of Ora Rosen, M.D. as part of my M.D.-Ph.D. training, I used biochemical and molecular techniques to dissect the mechanisms of signal transduction in a well characterized receptor system, the human insulin receptor. Last July I completed my clinical training in neurology, during which I spent some time in the laboratory of Eric Nestler, M.D., Ph.D. in the Abraham Ribicoff Research Facilities of the Yale University Department of Neurology and Psychiatry. Now, as an Assistant Professor in the Departments of Neurology and Psychiatry I seek to establish a laboratory investigating the roles of neurotrophic growth factors and their signaling pathways in the pathogenesis and treatment of neurologic and psychiatric diseases, particularly drug addiction. I have chosen to continue under the mentorship of Dr. Nestler, and within the Ribicoff Facilities, to learn the fundamentals of neuroscience, neuropharmacology, and the biological basis of drug addiction, while developing my research program. This MCSDA would greatly facilitate my development as an independent neuroscientist by supporting these training and research activities and guaranteeing that I may devote a majority of my time and effort to research. Drug addiction is one of the most prevalent, costly, and intractable personal and societal illnesses in this country. Persistent drug dependence and cravings are hallmarks of addiction and very likely represent an underlying process of drug-induced neural plasticity. The pharmacological and anatomic features of addiction have been extensively characterized in human and animal studies. Dr. Nestler and his colleagues have been at the forefront of defining the biochemical and molecular adaptations due to drugs of abuse. Dopaminergic ventral tegmental area (VTA) neurons are thought to be involved in mediating the rewarding properties of opiates, cocaine, and other drugs of abuse. Dr. Nestler's laboratory has defined a number of properties of opiates, cocaine, and other drugs of abuse. Dr. Nestler's laboratory has defined a number of persistent biochemical adaptations in the VTA, including alterations in tyrosine hydroxylase, neurofilaments, and neuron morphology. Neurotrophin infusion into the VTA can ameliorate at least some of the biochemical and behavioral changes due to drugs of abuse. Conversely, drugs of abuse may lead to VTA neuron plasticity via actions on neurotrophin signaling pathway elements. Therefore, a major goal of the research proposed in this MCSDA is to elucidate the role of neurotrophins and neurotrophin signaling pathway elements in the causes and reversal of persistent changes seen in dopaminergic VTA neurons associated with chronic exposure to drugs, using animal and cell-line models; where appropriate.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DA000302-03
Application #
2770047
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Lin, Geraline
Project Start
1996-09-30
Project End
2001-08-31
Budget Start
1998-09-30
Budget End
1999-08-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Neurology
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Russo, Scott J; Bolanos, Carlos A; Theobald, David E et al. (2007) IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci 10:93-9
Wolf, Daniel H; Nestler, Eric J; Russell, David S (2007) Regulation of neuronal PLCgamma by chronic morphine. Brain Res 1156:9-20
Mojsilovic-Petrovic, Jelena; Jeong, Goo-Bo; Crocker, Amanda et al. (2006) Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J Neurosci 26:9250-63
Sheehan, Teige P; Chambers, R Andrew; Russell, David S (2004) Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res Brain Res Rev 46:71-117
Sheehan, Teige P; Neve, Rachael L; Duman, Ronald S et al. (2003) Antidepressant effect of the calcium-activated tyrosine kinase Pyk2 in the lateral septum. Biol Psychiatry 54:540-51
Bolanos, Carlos A; Perrotti, Linda I; Edwards, Scott et al. (2003) Phospholipase Cgamma in distinct regions of the ventral tegmental area differentially modulates mood-related behaviors. J Neurosci 23:7569-76
Messer, C J; Eisch, A J; Carlezon Jr, W A et al. (2000) Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26:247-57
Numan, S; Russell, D S (1999) Discrete expression of insulin receptor substrate-4 mRNA in adult rat brain. Brain Res Mol Brain Res 72:97-102
Wolf, D H; Numan, S; Nestler, E J et al. (1999) Regulation of phospholipase Cgamma in the mesolimbic dopamine system by chronic morphine administration. J Neurochem 73:1520-8